drugset / Trial / NCT00384605

An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)

NCT00384605 ↗

Phase 3 Terminated 1000 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug.

Timeline

Start
2006-10
Primary completion
2008-01
Completion
2008-12

Outcome

Outcome not reported

Stopped: “The overall profile does not support development for obesity”

Drugs

EvaluationDrugModalityDoseRoute
Subject taranabant Unknown 0.5 mg —
Subject taranabant Unknown 1 mg —
Subject taranabant Unknown 2 mg —

Indications